The Asia Pacific biopharma excipients market size is poised to reach USD 791.4 million by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 6.63% during the forecast period. Patent expiry of blockbuster biologics such as Erbitux, Rituxan, Herceptin, Avastin, Aranesp, and Enbrel by 2030 is encouraging investments in biosimilars R&D by biopharma players. Soaring need for novel additives for development of biologics such as those enhancing lyophilization performance to improve stability of biologics is anticipated to boost the demand for excipients.
As per drug sales record of 2016, eight out of ten top-selling drugs are biologics. Upcoming patent expiry of biologics is leading to increased R&D for biosimilar formulations. Biopharma players in the market are adopting price reduction strategies in order to promote their products. This is triggering the need for consideration of pricing strategy among excipient manufacturers.
Presence of challenges in development of a stable form of biotherapeutic is urging manufacturers to develop novel excipients. Processing and storage of biomolecules are complicated as these products undergo degradation after a slight change in environmental conditions. Rising demand for chemicals that are compatible with these biomolecules and serve additional functions such as binding, bulking, and efficient delivery is stimulating the growth of the market. Technological advancements, such as implementation of nanotechnology in the development of novel compounds to enhance drug delivery, are likely to drive the market. For instance, an Australian provider of microencapsulation for drug delivery, Ceramisphere, expanded its operations for production of nanoparticles with extended-release capacity.
Furthermore, Asian countries such as India & China serve as major markets for biogenerics. Key pharmaceutical players in the market are increasing their R&D activities on follow-on-biologic. Biologics R&D is outsourced to CROs in the region as a consequence of cost efficiency provided by them, which is consequently boosting the demand for excipients.
Full Research Report On Asia Pacific Biopharma Excipients Market Analysis: www.grandviewresearch.com/industry-analysis/asia-pacific-biopharma-excipients-market
Further key findings from the report suggest:
Browse More Reports Of This Category By Grand View Research At: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the Asia Pacific biopharma excipients market on the basis of product and region:
Asia Pacific Biopharma Excipients Product Outlook (Volume, Tons; Revenue, USD Million, 2014 – 2025)
Asia Pacific Biopharma Excipients Regional Outlook (Volume, Tons; Revenue, USD Million, 2014 – 2025)
Explore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com
Media ContactCompany Name: Grand View Research, Inc.Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.Email: Send EmailPhone: 1-415-349-0058, Toll Free: 1-888-202-9519Address:28 2nd Street, Suite 3036 City: San FranciscoState: CaliforniaCountry: United StatesWebsite: www.grandviewresearch.com/industry-analysis/asia-pacific-biopharma-excipients-market